The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716
The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716
复制标题
DOI：
10.1007/s002130050893
复制
发表时间：
1999-03-01
影响因子：
3.4
通讯作者：
McGregor, IS
中科院分区：
文献类型：
--
作者：
Gallate, JE;McGregor, IS
给大鼠两周的家笼接触“接近啤酒”（一种尝起来像啤酒但含有< 0.5%乙醇v/v的饮料）或添加乙醇（4.5% v/v）的接近啤酒，其简称为“啤酒”。两组大鼠（近啤酒和啤酒），然后在一个“舔为基础的渐进比例范例”在操作室，其中不断增加的舔了近啤酒或啤酒交付每个连续的固定单位发出训练。在基线条件下，近啤酒和啤酒的断点（响应停止的比率）大致相等。然后测试大鼠5 HT（2A/2C）受体拮抗剂利坦色林（ritanserin）（0.625、2.5或10 mg/kg）、阿片受体拮抗剂纳洛酮（naloxone）（0.625、2.5或10 mg/kg）或大麻素CB 1受体拮抗剂SR 141716（0.3、1或3 mg/kg）的作用。所有三种药物都引起了啤酒组和接近啤酒组的断点和自发活动的剂量依赖性减少。然而，与饮用接近啤酒的大鼠相比，SR 141716和纳洛酮（而非利坦色林）对断点的影响在饮用啤酒的大鼠中显著更明显。在两组中，任何药物对自发活动的影响都没有这种差异。这些结果表明，SR 141716和纳洛酮对饮酒动机的影响不同，因此可能具有治疗酒精渴望的潜力。
Rats were given two weeks of home cage access to either "near-beer" (a beverage that tastes like beer but contains < 0.5% ethanol v/v) or near-beer with added ethanol (4.5% v/v), which is simply referred to as "beer". The two groups of rats (near-beer and beer) were then trained on a "lick-based progressive ratio paradigm" in operant chambers in which an ever increasing number of licks had to be emitted for each successive fixed unit of near-beer or beer delivered. Break points (the ratio at which responding ceased) for near-beer and beer were approximately equal under baseline conditions. Rats were then tested for the effects of the 5HT(2A/2C) receptor antagonist ritanserin (0.625, 2.5 or 10 mg/kg), the opioid receptor antagonist naloxone (0.625, 2.5 or 10 mg/kg) or the cannabinoid CB1 receptor antagonist SR 141716 (0.3, 1 or 3 mg/kg). All three drugs caused a dose-dependent reduction of break-points and locomotor activity in both the beer and near-beer groups. However, the effects of SR 141716 and naloxone, but not ritanserin, on breakpoints were significantly more pronounced on rats drinking beer compared to those drinking near-beer. There were no such differential effects of any of the drugs on locomotor activity across the two groups. These results suggest that both SR 141716 and naloxone differentially affect the motivation to consume alcoholic beverages and may thus have potential as drugs for the treatment of alcohol craving.